Imatinib methanesulfonate reduces hyperphosphorylation of tau following repeated peripheral exposure to lipopolysaccharide

Highlights • 7 i.p. injections of LPS leads to hippocampal tau phosphorylation. • i.p. injections of LPS leads to increased hippocampal tau expression. • Imatinib blocks both increased tau expression and phosphorylation in the hippocampus. • Results suggest inflammation-induced Aβ leads to tau phosp...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience 2016-09, Vol.331, p.72-77
Main Authors: Gardner, L.E, White, J.D, Eimerbrink, M.J, Boehm, G.W, Chumley, M.J
Format: Article
Language:English
Subjects:
Alzheimer’s Disease
Amyloid beta-Peptides - metabolism
amyloid-beta
Animals
Blotting, Western
Body Weight - drug effects
Disease Models, Animal
Hippocampus - drug effects
Hippocampus - immunology
hyperphosphorylated tau
Imatinib Mesylate - pharmacology
imatinib methane sulfonate
lipopolysaccharide
Lipopolysaccharides
Male
Mice, Inbred C57BL
Neurology
Phosphorylation - drug effects
Protein Kinase Inhibitors - pharmacology
tau Proteins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • 7 i.p. injections of LPS leads to hippocampal tau phosphorylation. • i.p. injections of LPS leads to increased hippocampal tau expression. • Imatinib blocks both increased tau expression and phosphorylation in the hippocampus. • Results suggest inflammation-induced Aβ leads to tau phosphorylation and expression.
ISSN:0306-4522
1873-7544
DOI:10.1016/j.neuroscience.2016.06.007